Propionic Acidemia

2
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
2100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Moderna
ModernaCAMBRIDGE, MA
2 programs
2
mRNA-3927Phase 1/2RNA Therapeutic1 trial
mRNA-3927Phase 1/2RNA Therapeutic1 trial
Active Trials
NCT04159103Recruiting77Est. Aug 2027
NCT05130437Recruiting50Est. Dec 2031

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
ModernamRNA-3927
ModernamRNA-3927

Clinical Trials (2)

Total enrollment: 127 patients across 2 trials

NCT05130437ModernamRNA-3927

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

Start: Nov 2021Est. completion: Dec 203150 patients
Phase 1/2Recruiting
NCT04159103ModernamRNA-3927

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

Start: Apr 2021Est. completion: Aug 202777 patients
Phase 1/2Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 127 patients
1 companies competing in this space